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T he Pediatric Regulation (EC) 1901/2006 in the EuropeanUnion (EU) and the Pediatric Research Equity Act and the
Best Pharmaceuticals for Children Act in the United States aim
to ensure that medicines for use in children are of high quality,
are ethically researched, and are authorized appropriately.
Such an assessment requires clinically robust and relevant
data. However, the conduct of pediatric clinical trials has
proved difﬁcult because of the rarity of the diseases and gaps
in knowledge in younger populations, leading to a general
concern internationally that, depending on the disease and age
of the child, 50% to 80% of children are still treated off label.1–3
Over the years, this gap in available evidence has led to serious
unintended harms. For example, the off-label pediatric use of
paroxetine was associated with an increased risk of suicidal
ideation and hostility, resulting in warnings by regulators that
the medicine should not be used in children and adolescents.4
In addition, local differences related to regulatory require-
ments, operational practicalities, standards of care, or cultural
expectations are creating hurdles to conduct multiregional
pediatric drug studies and develop pediatric clinical trials
networks required when developing drugs for rare diseases.
Many efforts have been taken among the regulatory agenc-
ies in recent years to achieve global regulatory harmonization,
which have been helpful to mitigate these challenges in other
areas.5,6 Over the past 3 years, international experts convened
to revise the ICH (International Council for Harmonisation) E11
guideline on clinical investigations of medicinal products in
pediatric populations to harmonize approaches to pediatric
extrapolation, striving to reduce substantial differences
between regions in the acceptance of data for global pediatric
medicine development programs.7,8 In addition, there are other
activities aiming at a more targeted harmonization at the
product or therapeutic level. For example, there are monthly
teleconferences among the US Food and Drug Administration,
European Medicines Agency, Health Canada, Pharmaceuticals
and Medical Devices Agency in Japan, and Therapeutic Goods
Administration in Australia to exchange evolving science and
discuss the current regulatory approaches for speciﬁc product
applications in pediatrics.9 We have harmonized some regula-
tory approaches for certain pediatric indications, such as
pediatric inﬂammatory bowel disease and Gaucher disease.5,6
These concerns and challenges apply also to the treatment
of children with pulmonary arterial hypertension (PAH).
Pediatric PAH is a rare and complex condition associated
with diverse cardiac, pulmonary, and systemic diseases, with
signiﬁcant morbidity and mortality. It shares some similarities
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with adult PAH, but there are important known differences in
vascular function, fetal origins of disease, growth and
development, genetics, natural history, underlying disease,
responses of the right ventricle, responsiveness to PAH-
speciﬁc therapies, and gaps in knowledge, particularly in the
youngest age groups.10
Because of the limitations in conducting pediatric studies,
therapeutic strategies used for adult PAH have not been
studied sufﬁciently in children to allow the deﬁnition of
potential toxicities or optimal dosing. Hence, the lack of
randomized clinical trials in pediatrics makes it difﬁcult to
deliver strong guidelines. On the basis of uncontrolled studies
and one randomized controlled trial for sildenaﬁl, STARTS-1
(Sildenaﬁl in Treatment-Na€ıve Children, Aged 1–17 Years,
With Pulmonary Arterial Hypertension), and experts’ consen-
sus, recommendations for extrapolating a pharmacological
treatment algorithm to pediatric PAH were made at the ﬁfth
World Symposium for Pulmonary Hypertension held in Nice,
France, in 2013.11
Therefore, the European Medicines Agency, the US Food
and Drug Administration, and Health Canada coorganized a
workshop12 to discuss the requirements for the development
of medicines for pediatric PAH that could address the high
unmet medical needs of children.
This report summarizes the main ideas and solutions
proposed during the meeting. Ultimately, the goal is to
provide a framework to further global development of
successful strategies and alternative end points for pediatric
drug development in PAH.
The data that support the ﬁndings of the survey are provided in
Data S1. Theworkshop brought together leading experts in PAH
and PAH stakeholders across the globe, including regulators,
researchers, clinicians, healthcare professionals, patients, and
pharmaceutical industry representatives. The objectives of the
workshop were to analyze the problems related to the conduct
of clinical trials in children with PAH, to reﬁne end points and
study designs to address the challenges identiﬁed, and to set
priorities for future research and development aspects of
speciﬁc medicines as well as provide medicine developers with
more advice speciﬁc to global pediatric drug development.
Current Status of Drug Development in Pediatric
PAH
Randomized controlled trials have shaped advances in the
care of adults with cardiovascular disease and are regarded as
the gold standard design to provide evidence for regulatory
approval for cardiovascular medicines. However, there are
many challenges to relying exclusively on randomized clinical
drug trials in adults to address the unique needs of children.
Such studies cannot always be conducted in rare pediatric
diseases, such as PAH. Because of these challenges, of the 9
products authorized for adults with PAH in the EU and
Canada, and 11 in the United States, only 2 of these products,
sildenaﬁl and bosentan, are authorized for children in the EU
and United States, respectively (Table 1). The complexity is
increased in the case of the pediatric PAH population because
of the many associated conditions that fragment the classi-
ﬁcation of pediatric PAH, which leaves only a relatively small
number of patients with PAH at each center, facing a high
number of competing medicinal products.
The lack of suitable clinical end points is another important
challenge for conducting pediatric clinical trials. End points
used in adults, such as the use of the 6-MinuteWalking Distance
(6MWD) Test, cannot be used in all pediatric age subsets.
Furthermore, there is a lack of consensus about the use of right-
sided heart catheterization to obtain hemodynamic end points
in pediatric clinical trials. This is confounded by a lack of
adequate alternative end points because of gaps in knowledge
related to methods to evaluate how a child and adolescent feel
and function across the age spectrum in response to therapy.
These challenges have limited the use of methods commonly
used in pediatric development, such as extrapolation. Method-
ological tools, such as extrapolation, can optimize obtaining
information about children involved in clinical studies by
predicting how a medicine may work in children and adoles-
cents on the basis of studies conducted in adults.13–15
This situation has resulted in a lack of equipoise after
marketing authorization for new investigational drugs in
adults, making it even more difﬁcult to enroll children, and
contributes to off-label use, which can increase the risk of
inadequate dosing and results in lack of pediatric safety data.
The main points of tension are related to ﬁnding the adequate
balance between early access and sufﬁcient exposure of
children during pediatric trials for safety and adequate dosing;
considerations should also be given about ethical and medical
aspects, particularly related to end points.
Premeeting Survey of Patients and Their Families,
Healthcare Professionals, and Drug Developers
on Pediatric PAH Drug Development
An online survey was conducted ahead of the workshop
among all interested stakeholders to gather as much infor-
mation as possible and facilitate an informed discussion.
Healthcare professionals and patients in the EU, United
States, and Canada were contacted as well as one expert in
Japan. Survey questions were related to pathophysiological
features, pharmacological behavior, mechanism of action,
extrapolation, end points, quality of life, and clinical trials.
Respondents included 22 healthcare professionals treating
adults and children with PAH, 4 industry participants involved
in PAH drug development, 26 parents of children with PAH,
and 1 adolescent patient with PAH.
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For the healthcare professionals, speciﬁc points considered
central to the discussion were related to the lack of sufﬁcient
outcome measures that are applicable to young children with
PAH, including the lack of established biomarkers that can
predict disease risk, severity, and disease progression.
Experts welcomed the opportunity to investigate the use of
activity measurement for the pediatric population and
acknowledged the possibility of using noninvasive techniques
and candidate surrogate markers, such as selected imaging
(echocardiography or cardiac magnetic resonance imaging)
parameters or NT-proBNP (N-terminal pro-B-type natriuretic
peptide).
With regard to patients, major topics for discussion were
related to off-label use, end points, daily monitoring, and
participation in clinical trials. Most of the patients who
participated in the survey and the workshop were not
concerned about the off-label use of drugs because they
trust their physicians. Also, only a couple of medicinal
products are licensed for children in their respective coun-
tries, leaving patients with no other choice than to accept the
available therapy(-ies) even when used off label. In addition,
for medicinal products already licensed for adults, patients in
many countries do not have an incentive to enroll in clinical
studies because they can access these medicinal products for
pediatric use outside of a clinical trial.
Parents expressed concerns about the use of invasive
procedures, such as right-sided heart catheterization, to
obtain hemodynamic end points in clinical trials and the use
of the 6MWD Test, which was not considered a good
indicator of the child’s health status on its own. Parents take
many other variables into account to monitor the child’s
health status, and many are regularly monitoring oxygen
saturation. The most important signs for parents that their
child’s health is deteriorating are an observed increase in
fatigue and change in physical appearance. In addition, most
of the parents were supportive of the idea to self-report
speciﬁc symptoms and welcomed the possibility to gather
and report data on quality of life and other important
information through technologies, such as smartphone
applications.
Representatives from the pharmaceutical industry acknowl-
edged the challenges of conducting studies in pediatric PAH,
but also welcomed clariﬁcations about assumptions and
method (eg, knowledge on appropriate end points and
applicability of extrapolation) to minimize the risk of incon-
clusive study results. More important, the level of evidence
required for licensing should not differ substantially between
the different regulatory regions and stakeholders. Streamlined
clinical development programs that would meet global
requirements would help optimize the use of resources and
achieve success in a reasonable time.
At the meeting, it was agreed that because of these
various perceptions by stakeholders, pediatric development
programs are disconnected from their respective adult
programs. Such disconnections impede the design, recruit-
ment, and conduct of studies in children, leading to
signiﬁcant delays. It is important to help ensure that the
data generated in adults and children will address the
scientiﬁc questions that are important for licensing for
children in a timely manner.
Table 1. Overview of Medicines Available for Use in PAH for Adults and Children




EU United States Canada EU United States Canada
Prostacyclin analogue Treprostinil No Yes Yes No No No
Selexipag Yes Yes Yes No No No
Treprostinil diethanolamine No Yes No No No No
Iloprost Yes Yes No No No No
Epoprostenol Yes Yes Yes No No No




Ambrisentan Yes Yes Yes No No No
Macitentan Yes Yes Yes No No No
Phosphodiesterase type 5 inhibitor Sildenafil Yes Yes Yes Yes No No
Tadalafil Yes Yes Yes No No No
Guanylate cyclase stimulators Riociguat Yes Yes Yes No No No
Pediatric indications have not been granted; however, results of pharmacokinetic studies in the different pediatric age groups are summarized in the Summary of Product Characteristics,
with a comparison to adults. Uncertainties caused by limited experience are also stated. EU indicates European Union; PAH, pulmonary arterial hypertension.
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Trial Design in Pediatric PAH: Points to Consider
and Paradigm Shift
Transfer of information from the adult to the pediatric
population and use of existing knowledge
Drugs approved to treat PAH in adults are typically based on a
single, well-controlled clinical trial showing statistically signif-
icant improvement in exercise capacity or, more recently,
improvements in a composite of mortality and morbidity end
points (Table 2). The pivotal efﬁcacy trial is usually supported
by a smaller phase 2 study that relies on pharmacodynamic
end points (eg, hemodynamic biomarkers obtained by right-
sided heart catheterization) to show dose-response and guide
selection of dosing regimens. On the basis of global
requirements for the use of extrapolation,8,15 the use of a
drug in the pediatric population can be supported by adult
efﬁcacy data in 2 ways:
1. The data from the adult population support the use in
pediatrics for the PAH indication. The efﬁcacy is estab-
lished in pediatric populations on the basis of an adequate
and well-controlled clinical efﬁcacy and safety trial.
Efﬁcacy in the pediatric population is assessed using an
appropriate clinical end point.
2. The efﬁcacy in the pediatric population is extrapolated
from adult data. Evidence for effectiveness is based on
adequate and well-controlled clinical trials in adults, with
additional supporting data in the speciﬁc pediatric popu-
lation, typically guided by biomarker and pharmacokinetic
data. In this scenario, the pathophysiological features of
some forms of PAH are proved sufﬁciently similar in adults
and children, and there is a clear understanding of the
basis for the drug’s beneﬁt (mechanism of action,
ontogeny of the drug target, and disease in adults and
children) and a biomarker with which to assess the drug
effects in the pediatric population.
Pharmacokinetic and safety data cannot be extrapolated
from adults and would need to be assessed in the pediatric
population.
On the basis of the data presented at the meeting and
existing knowledge at the time of the workshop, there was
consensus among stakeholders that our understanding of the
pathophysiological features of various PAH subgroups is still
insufﬁcient to draw detailed comparison between those seen
in the adult versus the child, and consequently to extrapolate
efﬁcacy as a general rule.
A positive example in which progress has been made
through adequate data collection over the past years and in
which existing knowledge can translate in facilitating regula-
tory requirements is idiopathic PAH and some forms of
associated PAH in adults and children, making progress
toward extrapolation of efﬁcacy possible. Such progress has
been integrated by the Committee for Medicinal Products for
Table 2. Summary of Efﬁcacy End Points Used to Obtain Regulatory Approval of Medicines for Use in PAH for Adults and Children
End Points Used
Study Population and Numbers
of Studies Products Approved Limitations if Used in Pediatric Trials
Increase in 6-min
walking distance16–20








• Need large sample size because of variability
• Not reliable in children less than 7 y
A composite of time to
the first morbidity or
mortality event21,22
Adults (2 studies) Macitentan
Selexipag
• To further optimize and define relevant
components of clinical worsening in
pediatric patients with PAH
• Need relatively large sample size
Increase in O2 consumption
at peak exercise via CPET23
Pediatrics (1 study) Sildenafil (EU)* 51% of children were developmentally
unable to perform CPET in this trial
ΔPVR/ΔPVRi assessed by RHC24 Pediatrics (1 study) Bosentan (United
States and Health Canada)
End points collected by invasive RHC are
not supported for the purpose of pediatric
trials because of ethical concerns about the
risk of death and severe adverse events
related to the procedure
CPET indicates cardiopulmonary exercise testing; EU, European Union; PAH, pulmonary arterial hypertension; ΔPVR, change in pulmonary vascular resistance; ΔPVRi, ΔPVR index; RHC,
right-sided heart catheterization.
*Sildenaﬁl is approved in the EU, but not in the United States and Canada, on the basis of the evidence that long-term mortality showed a dose-related adverse trend on mortality.
DOI: 10.1161/JAHA.118.011306 Journal of the American Heart Association 4
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Human Use, which is the European Medicines Agency’s
committee responsible for human medicines in the pediatric
addendum to its guideline on the clinical investigations of
medicinal products for the treatment of PAH. Such an
agreement means that there would no longer always be the
necessity to run studies in which the main aim is to conﬁrm
clinical beneﬁts, and it might not necessarily be required to
conduct placebo-controlled trials. Placebo control can lead to
recruitment issues, even for short-term placebo withdrawal
studies, as particularly highlighted by the patient’s represen-
tatives. The use of extrapolation of efﬁcacy from adults to
children could allow pediatric licensing on the basis of studies
evaluating pharmacokinetics, pharmacodynamics, and safety
in the pediatric population.25 For classes of products already
authorized, and with appropriate end points, adult and
pediatric PAH clinical programs may proceed simultaneously,
leading to timely access for children. To date, only bosentan
has obtained a claim for use in the pediatric population on the
basis of an extrapolation approach in the United States.
During the meeting, stakeholders agreed that pharmacoki-
netics data alone (ie, matching blood concentrations in
pediatric patients with PAH to those achieved in adult patients
with PAH) would not be sufﬁcient for extrapolation. There is
the need to conﬁrm the adequate doses with pharmacody-
namics end points. Studies focusing on pharmacokinetics/
pharmacodynamics may not need a control arm of another
medicinal compound or placebo, but could be dose controlled
with at least 3 doses to characterize the dose-response curve.
Further considerations to the pharmacokinetics/pharmaco-
dynamics study design will need to be developed, particularly
paying careful attention to pediatric clinical pharmacological
features early in study design, which can also help to optimize
initial dose selection and data sampling.
In addition, although extrapolation might allow a reduction
in the number of pediatric trial participants, it was acknowl-
edged that extrapolation in pediatric PAH is still at a learning
stage and there is a need for further data to enhance our
current knowledge, speciﬁcally with respect to how develop-
mental growth and maturation would impact pharmacokinet-
ics/pharmacodynamics outcomes. Furthermore, efﬁcacy data
may have some residual uncertainties stemming from the
limited populations and feasibility reasons at the time of initial
approval. To address uncertainties at the time of marketing
authorization, postauthorization studies that are performed in
patient registries in which patients are recruited on the basis
of a disease (ie, disease registry) rather than on the basis of a
speciﬁc drug exposure can be a useful tool as they may
provide robust data on disease epidemiological characteris-
tics, patients’ characteristics, and current standard of care.
Conversely, experience shows that when there is the need for
collaboration between registries, it is contingent on agree-
ment on data ownership and sharing, timelines, established
protocols and statistical analysis plans, consideration of
methodological differences between data sources because of
consideration of adequate sample size, and provision of
operational and scientiﬁc support (ie, for programming and
statistical analyses).26 These pediatric-speciﬁc disease reg-
istries, such as the TOPP (Tracking Outcomes and Practice in
Pediatric Pulmonary Hypertension) registry, and, in the future,
databases that accurately reﬂect the phenotype and genotype
of neonatal and childhood PAH may prove of particular
relevance to elucidate the natural history of PAH; these are
critical factors that modulate outcomes and responses to
therapies and related research questions. To address the
need to better characterize pediatric PAH, the TOPP registry
was initiated in January 2008 and is a global, prospective
study designed to provide information about demographics,
treatment, and outcomes in pediatric pulmonary hyperten-
sion. Furthermore, one of the tools to be considered is the
model of real-world data that can help to overcome some of
the challenges. However, the planning for collection of
structured data is particularly important to be set up a priori
with a view to be successfully implemented.
Consequently, it was agreed that the identiﬁcation of the
evidence necessary to inform the pediatric drug development
program in pediatric PAH may require considerations for
additional longitudinal systematic collection of data across
developments in both adults and children, during these
learning stages. The pharmaceutical industry participants
considered the use of data pooling for validation of a
pharmacodynamics parameter to enable extrapolation as a
potential solution. For example, working across industry and
sharing available placebo data or using available supportive
data (eg, from other products with a similar mechanism of
action, registries, or open-label data) could contribute to end
point evaluation and validation.
Evidence-based medicine for pediatric PAH and end
points
Regulatory approval of a drug traditionally requires demon-
stration that it improves a clinical outcome (ie, how a
patient feels, functions, or survives) or a validated surrogate
for such an outcome. Improving survival, improving exercise
capacity, preventing hospitalization, and improving quality of
life are all important treatment goals and have a direct
impact on patients with PAH and their families. A surrogate
end point is deﬁned as an end point that is used in clinical
trials as a substitute for a direct measure of how a patient
feels, functions, or survives. A surrogate end point does not
measure the clinical beneﬁt of primary interest in and of
itself, but rather is expected to predict that clinical beneﬁt
or harm on the basis of epidemiologic, therapeutic,
pathophysiologic, or other scientiﬁc evidence.27,28 At
present, there are no validated surrogate end points that
DOI: 10.1161/JAHA.118.011306 Journal of the American Heart Association 5
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can substitute for clinical end points to support tradi-
tional or accelerated approval of new therapies for pediatric
PAH.
Despite emerging recent data on clinical course, prognos-
ticators, treatment strategies, the deﬁnition of treatment
targets and the potential of (surrogate) end points in pediatric
PAH, clinical research in pediatric PAH has a lack of age-
appropriate clinical end points, including the lack of estab-
lished biomarkers that can predict disease risk, severity, and
disease progression. A summary of potential useful noninva-
sive clinical end points is presented in Table 3. The applica-
bility of each end point in pediatric clinical trials is described
below in more detail.
Interventional clinical trials in adults have commonly used
the 6MWD Test to demonstrate efﬁcacy for drug approval;
therefore, this end point could be used in pediatric patients
developmentally able to perform the test.29–31 Unfortunately,
young children (aged <7 years) cannot reliably perform the
test, making this a suboptimal primary end point in a study of
the full age range of children. Likewise, cardiopulmonary
exercise testing has failed as a primary end point in pediatric
PAH sildenaﬁl efﬁcacy trials as 51% of children were unable to
perform it.32
Clinical worsening as a composite end point in adult trials
in PAH has incorporated certain soft components, such as
need for more therapy or reductions in exercise capacity, and
poses challenges in terms of interpretability in PAH.33
Regulators have not considered the magnitude of drug effects
on this end point to be of critical concern in granting such
claims in adults. Thus, a program seeking such a claim in
children would not need a predicate ﬁnding in adults and
could be applied to forms of PAH dissimilar to those seen in
adults. For instance, as shown in Table 2,16–24 2 recent
studies in adults used a composite end point (ie, time to the
ﬁrst morbidity or mortality event) as the primary end point.
The ﬁrst morbidity or mortality events included (1) death, (2)
onset of a treatment-emergent adverse event with a fatal
outcome occurring within 4 weeks of study treatment
discontinuation, (3) atrial septostomy or hospitalization for
atrial septostomy, (4) lung transplantation or hospitalization
for lung transplantation, (5) initiation of intravenous or
subcutaneous prostanoids (eg, epoprostenol or treprostinil)/
hospitalization for initiation of intravenous or subcutaneous
prostanoids, or (6) other worsening of PAH. Such an end point
could potentially be used in pediatric PAH trials to seek a
claim related to disease progression in regions where such
Table 3. Noninvasive End Points With Potential Use as End Points in Clinical Trials in Children
End Point Modality
Potential Treatment Goals
to be Considered Strengths Limitations
WHO-FC WHO-FC improvement • Convenience
• Predictive of transplant-free
survival in pediatric PAH
• Variability in classifications among clinicians
• Definitions of symptoms may differ and not be
reliable in children
NT-proBNP NT-proBNP lowering • Simple procedure (plasma)
• Likely predictive of transplant-free
survival in pediatric PAH prognosis
• Not a specific indicator for PAH only
• Impacted by cause of PAH
• The normal value of NT-proBNP in children
can vary with age
Echocardiography • TAPSE improvement
• 3-Dimensional right
ventricular function
• Fractional area change
• Widely used for monitoring
in patient population
• 3-Dimensional echocardiography
offers new options with end points
• High operator variability
• Likely larger sample size
• No consensus on which echocardiographic
end point should be used as a primary outcome
Actigraphy • Physical activity count
• Heart rate variability
• Children friendly
• Simple and can continuously record
physical activity for days and weeks
• Correlates with 6MWD Test,
mPAP, and PRVi
• Sensitive and, thus, potentially
requires smaller sample size
• Needs to be validated in an interventional trial
• Needs to optimize the cutoff values for different
levels of physical activities across different devices
• Seasonal and school/holiday influences
PRO Not studied Direct measurement of how a patient
feels, functions, and survives
Not being developed
6MWD indicates 6-Minute Walking Distance; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAH, pulmonary arterial hypertension; PRO,
patient-reported outcome; PVRi, pulmonary vascular resistance index; TAPSE, tricuspid annular plane systolic excursion; WHO-FC, World Health Organization functional class.
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claims are explicitly written into the label.32,34,35 A recent
study in children with PAH demonstrated the feasibility of
such combined end points in children and has shown that the
end point components of death, lung transplantation, hospi-
talization, initiation of intravenous prostanoids, and functional
deterioration occurred with a longitudinal event rate of 10.1,
2.5, 21.4, 9.4, and 48.1 events per 100 person-years,
respectively.36 Furthermore, it showed the soft components
included in the composite were highly predictive for death or
lung transplantation.
Cardiac catheterization with measurement of invasive
hemodynamics and calculation of pulmonary vascular resis-
tance, a nontherapeutic procedure, remains the gold standard
for diagnosing PAH, evaluating disease severity, and following
treatment responses in children and adults. Hemodynamic
parameters have been shown to correlate with prognosis in
children.34 The US Food and Drug Administration considers
pulmonary vascular resistance as a translational surrogate
end point for extrapolation. The relationship between exercise
capacity (measured by 6MWD Test) and pulmonary vascular
resistance was developed using patient-level data from 12
placebo-controlled trials (4 drug classes, 9 drugs) of approved
PAH treatments in adults. The effect of bosentan on pul-
monary vascular resistance in children, as shown in one early
study,35 corresponded to a likely improvement in exercise
capacity in adults and permitted the extrapolation of efﬁcacy
from adults to children with a spectrum of PAH similar to
adults, and thus, to support approval of bosentan for the
treatment of PAH in pediatric patients with idiopathic or
congenital PAH. However, there are ethical concerns about
using cardiac catheterization to obtain end points in future
pediatric clinical trials.32 Deaths and severe adverse events
are reported in 1% to 3% of procedures during hemodynamic
assessments, such as during the sildenaﬁl pediatric trial and
in registries and administrative databases.32,37,38
Echocardiography can provide several estimates of hemo-
dynamic function that closely correlate with measurements
obtained by right-sided heart catheterization,39 and echocar-
diographic variables have been identiﬁed as predictors of
outcome and are suggested as a treatment target in children
with PAH.39,40 Echocardiography, however, is subject to
signiﬁcant operator and interpretation variability.41 The reli-
ability of echocardiography has not been validated in adult
interventional trials to detect treatment effect, so future
randomized controlled trials could include echocardiographic
variables as secondary outcomes to determine if these may
be suitable surrogate end points to be used to bridge another
vasodilator for PAH from adults to children.
In adults, BNP is a useful tool to assess mortality risk,
progression of the disease, and response to therapy. Change
in BNP measurements over time typically trend with changes
in classic hemodynamic and echocardiographic parameters of
disease severity for children with PAH. In the Netherlands, a
national registry, and a related meta-analysis, NT-proBNP was
identiﬁed as a treatment goal and prognostic factor in
children.42
Quality of life, functional assessment, and involvement
of patients
World Health Organization functional class has been used to
monitor symptoms in both adults and children with PAH and
is based on information on symptoms with activity and at
rest, provided by the patient and/or the parents and
categorized by the physician in 4 predeﬁned classes. World
Health Organization functional class is commonly used and
easy to be performed in children. Although World Health
Organization functional class is acceptable as a primary end
point in the pediatric PAH interventional trials, this end
point may require a large sample size in an interventional
trial.43,44
Health status assessment in pediatric PAH trials could be a
patient- or parent-reported outcome that directly measures
how a patient feels or functions (or via parental assessment).
Patient activity could be recorded through noninvasive
wearable biosensors. These need to be studied in the target
population to inform patient activity measurement in study
design. Actigraphy is reliably measured in adults with PAH,45
and lower activity is linked with symptoms of fatigue and low
energy and lower 6MWD Test (Spearman rank correla-
tion=0.72, P<0.001).45,46 A recent study of children 3 to
17 years old with PAH demonstrated that actigraphy is a
promising candidate as an end point.47 It is currently unknown
whether actigraphy can detect treatment response in either
adults or children with PAH, for what ages it might be
appropriate, and exactly what parameter to use as an end
point (activity counts or time spent in moderate or vigorous
activity).
Areas of Consensus and Future Developments for
Pediatric PAH
After 10 years since the entry into force of the EU Paediatric
Medicine Regulation (EC No. 1901/2006), the number of new
medicines developed for pediatric PAH continues to be
insufﬁcient. For ethical and feasibility reasons, there was
agreement that there is a need to be innovative in pediatric
PAH drug development programs. End points may need to be
different in different age groups. All potential sources of data
should be used for planning and designing drug develop-
ments, and validation should be performed. Sponsors, regu-
lators, patients, parents, and academics should work together
to ensure this happens. Industry representatives see global
regulatory harmonization as a key to success and offered
consideration for pooling data from registries, using open-
DOI: 10.1161/JAHA.118.011306 Journal of the American Heart Association 7
















 http://ahajournals.org by on October 7, 2019
label data, and supporting data from approved compounds
with similar mechanisms of action to facilitate the develop-
ment of a common scientiﬁc approach. However, although for
regulators, the geographical spread of a registry network is a
key factor for understanding treatment practices and out-
comes, data need to be of appropriate quality. As a future
step, having tools, such as the TOPP registry, qualiﬁed for
pharmacoepidemiology studies as the ECFSPR (European
Cystic Fibrosis Society Patient Registry) would allow their use
for regulatory purposes.48 In addition, historically, clinical trial
data have been collected in diverse data formats in indepen-
dent studies. In the context of extrapolation, comparative
effectiveness research, comparing the beneﬁts and harms of
interventions for clinical conditions, can accelerate pediatric
development, particularly in rare disease areas. For example,
the development of a set of outcomes for PAH would enable
efﬁcient data collection, data integration, and regulatory
review, particularly if measured and reported, as a minimum,
in all clinical trials as it would allow the reuse of clinical data.
Therefore, although the foregoing discussion addresses
some of the considerations for obtaining reliable information
to support use of drugs for pediatric forms of PAH, regulators
remain open to discuss alternative pathways, novel end
points, and novel trial designs.
Another important aspect is unique feasibility issues
affecting pediatric drug development, which are related to
the limited pediatric-speciﬁc resources at research centers
and the scarcity of dedicated pediatric trial networks. Thus,
there is the need to build these clinical trial networks to
contribute to increasing patient access to trials and allow
investigators to conduct multicenter and multinational trials
while decreasing the time to complete a trial. To overcome
some of the hurdles, it is recommended to involve all
stakeholders, including patients, parents, and their organiza-
tions, as well as pediatric research networks in the concep-
tion, design, and conduct of research to improve the ethical,
scientiﬁc, and clinical quality of pediatric studies.
Supported by public/private partnership, pediatric oncol-
ogy is a successful example for which in the past years,
because the landscape of therapeutic innovations for cancer
has changed, with many more new drugs in development but
with still few of them reaching children, several represen-
tatives from academic research, pharmaceutical companies,
regulatory drug agencies, policy makers, as well as patient/
parent advocates joined their forces and created the
ACCELERATE Multistakeholder Platform in Europe.49 The
global pediatric pulmonary hypertension community, orga-
nized in the Association for Pediatric Pulmonary Hyperten-
sion and driving the multinational TOPP registry, has made
already an important step in the direction toward such a
network, and should follow the path set by pediatric
oncology.
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